{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:08Z","timestamp":1786994408702,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.msard.2022.104185","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T09:31:07Z","timestamp":1663407067000},"page":"104185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["What are the trends in the treatment of multiple sclerosis in recent studies? \u2013 A bibliometric analysis with global productivity during 1980\u20132021"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5097-3594","authenticated-orcid":false,"given":"Serdar","family":"Ayka\u00e7","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Elia\u00e7\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104185_bib0001","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.msard.2022.104185_bib0002","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458514540357","article-title":"Bibliometric profile of the global scientific research on multiple sclerosis (2003\u20132012)","volume":"21","author":"Aleixandre-Benavent","year":"2015","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.msard.2022.104185_bib0003","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2174\/1871527318666190703102330","article-title":"Implications of vitamin D in multiple sclerosis and other neurodegenerative processes: bibliometric analysis and systematic review","volume":"18","author":"Caballero-Villarraso","year":"2019","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"4","key":"10.1016\/j.msard.2022.104185_bib0004","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/14737175.2021.1886926","article-title":"Gene and cell therapy and nanomedicine for the treatment of multiple sclerosis: bibliometric analysis and systematic review of clinical outcomes","volume":"21","author":"Caballero-Villarraso","year":"2021","journal-title":"Expert Rev. Neurother."},{"issue":"9856","key":"10.1016\/j.msard.2022.104185_bib0005","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.msard.2022.104185_bib0006","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"9268","key":"10.1016\/j.msard.2022.104185_bib0007","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.msard.2022.104185_bib0008","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.aller.2020.01.001","article-title":"Bibliometric analysis of publications on house dust mites during 1980\u20132018","volume":"48","author":"Demir","year":"2020","journal-title":"Allergol. Immunopathol."},{"key":"10.1016\/j.msard.2022.104185_bib0009","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","article-title":"How to conduct a bibliometric analysis: an overview and guidelines","volume":"133","author":"Donthu","year":"2021","journal-title":"J. Bus. Res."},{"issue":"9139","key":"10.1016\/j.msard.2022.104185_bib0010","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon \u03b2-1a in relapsing\/remitting multiple sclerosis PRISMS (prevention of relapses and disability by interferon \u03b2-1a subcutaneously in multiple sclerosis) study group","volume":"352","author":"Ebers","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.msard.2022.104185_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00011-018-1185-0","article-title":"A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future","volume":"68","author":"Gholamzad","year":"2019","journal-title":"Inflamm. Res."},{"issue":"3","key":"10.1016\/j.msard.2022.104185_bib0012","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/JASI.JASI_114_20","article-title":"Global research output of the cerebellum: yesterday, today, and tomorrow","volume":"69","author":"Golpinar","year":"2020","journal-title":"J. Anat. Soc. India"},{"issue":"12","key":"10.1016\/j.msard.2022.104185_bib0013","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2022.104185_bib0014","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2022.104185_bib0015","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group","volume":"343","author":"Jacobs","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.msard.2022.104185_bib0016","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2022.104185_bib0017","doi-asserted-by":"crossref","first-page":"421","DOI":"10.36472\/msd.v9i8.771","article-title":"The evolution of COVID-19 publications in pediatrics: a bibliometric analysis with research trends and global productivity: bibliometric analysis of COVID-19 publications in pediatrics","volume":"9","author":"Kaba","year":"2022","journal-title":"Med. Sci. Discov."},{"issue":"9139","key":"10.1016\/j.msard.2022.104185_bib0018","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon \u03b2-1b in treatment of secondary progressive multiple sclerosis","volume":"352","author":"Kappos","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.msard.2022.104185_bib0019","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s11126-021-09937-4","article-title":"Global scientific outputs of schizophrenia publications from 1975 to 2020: a bibliometric analysis","volume":"92","author":"Kiraz","year":"2021","journal-title":"Psychiatr. Q"},{"issue":"4","key":"10.1016\/j.msard.2022.104185_bib0020","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104185_bib0021","article-title":"Global scientific outputs of extracorporeal embrane oxygenation in COVID-19: a bibliometric overview","author":"Kosovali","year":"2022","journal-title":"Perfusion"},{"issue":"11","key":"10.1016\/j.msard.2022.104185_bib0022","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2022.104185_bib0023","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.104185_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104185_bib0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult. Scler. J."},{"issue":"9","key":"10.1016\/j.msard.2022.104185_bib0027","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2022.104185_bib0028","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.104185_bib0026","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.104185_bib0033","unstructured":"Rachel King, et al., 2020. Atlas of MS. 3rd ed. The Multiple Sclerosis International Federation September 3, 2020. www.atlasofms.org (accessed 1 june 2022). In this issue."},{"issue":"4","key":"10.1016\/j.msard.2022.104185_bib0029","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2022.104185_bib0030","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial","volume":"45","year":"1995","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.104185_bib0031","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104185_bib0032","unstructured":"The World Bank USA, 1945. The World Bank is an international organization that provides financing, advice, and research to developing nations to help advance their economies. https:\/\/data.worldbank.org\/indicator\/NY.GDP.MKTP.CD (accessed 1 June 2022)."},{"issue":"2","key":"10.1016\/j.msard.2022.104185_bib0034","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"issue":"14","key":"10.1016\/j.msard.2022.104185_bib0035","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:10:11Z","timestamp":1761901811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822006903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":35,"alternative-id":["S2211034822006903"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104185","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What are the trends in the treatment of multiple sclerosis in recent studies? \u2013 A bibliometric analysis with global productivity during 1980\u20132021","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104185"}}